Immune Design Corp. (NASDAQ:IMDZ) – Equities research analysts at Leerink Swann issued their Q3 2017 earnings per share (EPS) estimates for Immune Design Corp. in a research note issued to investors on Thursday. Leerink Swann analyst J. Chang expects that the biotechnology company will post earnings of ($0.74) per share for the quarter. Leerink Swann also issued estimates for Immune Design Corp.’s Q4 2017 earnings at ($0.76) EPS, FY2017 earnings at ($2.54) EPS and FY2018 earnings at ($2.22) EPS.

Immune Design Corp. (NASDAQ:IMDZ) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.11. The company had revenue of $0.73 million for the quarter, compared to analysts’ expectations of $1.50 million. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%.

TRADEMARK VIOLATION NOTICE: “Analysts Issue Forecasts for Immune Design Corp.’s Q3 2017 Earnings (IMDZ)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/28/analysts-issue-forecasts-for-immune-design-corp-s-q3-2017-earnings-imdz.html.

Several other research analysts have also recently weighed in on the company. ValuEngine raised Immune Design Corp. from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. BidaskClub cut Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. Zacks Investment Research raised Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research report on Tuesday, July 18th. Jefferies Group LLC reissued a “buy” rating and issued a $18.00 price objective on shares of Immune Design Corp. in a research report on Wednesday, June 28th. Finally, Cowen and Company reissued a “buy” rating on shares of Immune Design Corp. in a research report on Tuesday, June 6th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $14.50.

Immune Design Corp. (NASDAQ:IMDZ) opened at 8.15 on Monday. Immune Design Corp. has a 52 week low of $4.50 and a 52 week high of $13.05. The firm’s market cap is $208.79 million. The stock has a 50 day moving average of $9.61 and a 200 day moving average of $7.45.

In other news, Director Lewis W. Coleman purchased 8,000 shares of the company’s stock in a transaction dated Friday, July 7th. The shares were purchased at an average price of $9.27 per share, with a total value of $74,160.00. Following the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at $370,800. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Wayne Gombotz sold 10,000 shares of the company’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $11.43, for a total value of $114,300.00. Following the transaction, the insider now directly owns 33,054 shares in the company, valued at approximately $377,807.22. The disclosure for this sale can be found here. Insiders have bought a total of 30,000 shares of company stock worth $272,760 in the last ninety days. Insiders own 42.90% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bain Capital Public Equity Management LLC boosted its position in shares of Immune Design Corp. by 393.1% in the second quarter. Bain Capital Public Equity Management LLC now owns 389,400 shares of the biotechnology company’s stock worth $3,797,000 after buying an additional 310,433 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Immune Design Corp. by 118.7% in the second quarter. JPMorgan Chase & Co. now owns 530,702 shares of the biotechnology company’s stock worth $5,175,000 after buying an additional 288,009 shares in the last quarter. Victory Capital Management Inc. boosted its position in shares of Immune Design Corp. by 11.6% in the first quarter. Victory Capital Management Inc. now owns 1,937,554 shares of the biotechnology company’s stock worth $13,175,000 after buying an additional 202,149 shares in the last quarter. Sectoral Asset Management Inc purchased a new position in shares of Immune Design Corp. during the second quarter worth approximately $1,641,000. Finally, Numeric Investors LLC purchased a new position in shares of Immune Design Corp. during the second quarter worth approximately $1,641,000. 50.82% of the stock is currently owned by hedge funds and other institutional investors.

About Immune Design Corp.

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Earnings History and Estimates for Immune Design Corp. (NASDAQ:IMDZ)

Receive News & Stock Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related stocks with our FREE daily email newsletter.